- Home
- RCG vs LPCN Comparison
RCG vs LPCN Comparison
Compare RCG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCG
- LPCN
- Stock Information
- Founded
- RCG 1994
- LPCN 1997
- Country
- RCG United States
- LPCN United States
- Employees
- RCG N/A
- LPCN N/A
- Industry
- RCG Investment Managers
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- RCG Finance
- LPCN Health Care
- Exchange
- RCG Nasdaq
- LPCN Nasdaq
- Market Cap
- RCG 18.2M
- LPCN 16.1M
- IPO Year
- RCG N/A
- LPCN N/A
- Fundamental
- Price
- RCG $2.65
- LPCN $3.29
- Analyst Decision
- RCG
- LPCN Strong Buy
- Analyst Count
- RCG 0
- LPCN 2
- Target Price
- RCG N/A
- LPCN $9.00
- AVG Volume (30 Days)
- RCG 5.9K
- LPCN 59.4K
- Earning Date
- RCG 01-01-0001
- LPCN 08-07-2025
- Dividend Yield
- RCG 0.98%
- LPCN N/A
- EPS Growth
- RCG N/A
- LPCN N/A
- EPS
- RCG N/A
- LPCN N/A
- Revenue
- RCG N/A
- LPCN $3,674,834.00
- Revenue This Year
- RCG N/A
- LPCN N/A
- Revenue Next Year
- RCG N/A
- LPCN N/A
- P/E Ratio
- RCG N/A
- LPCN N/A
- Revenue Growth
- RCG N/A
- LPCN N/A
- 52 Week Low
- RCG $1.52
- LPCN $2.68
- 52 Week High
- RCG $1.90
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- RCG 49.02
- LPCN 51.52
- Support Level
- RCG $2.55
- LPCN $3.13
- Resistance Level
- RCG $2.68
- LPCN $3.53
- Average True Range (ATR)
- RCG 0.09
- LPCN 0.24
- MACD
- RCG -0.00
- LPCN 0.01
- Stochastic Oscillator
- RCG 40.00
- LPCN 48.33
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.